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How Ebola virus (EBOV) enters a host cell remains intri-
guingly mysterious to the public. Recently, a study led by 
George F Gao and his colleagues has unveiled how the 
primed glycoprotein on the envelope of EBOV binds to its 
endosomal receptor Niemann-Pick C1 (NPC1) molecule 
during the process of virus membrane fusion with the host 
cells, an essential step for viral entry (Wang et al., 2016). 
This fine resolution of the viral glycoprotein with NPC1 at 
the atomic level sheds light on the development of thera-
peutic inhibitors against EBOV infection. 
After the unprecedented EBOV outbreak in West Africa 
in 20132014, the global efforts have consolidated to de-
velop different kinds of vaccines and therapeutic drugs 
against EBOV. However, the evidence that EBOV can re-
side in the eyes and semen in convalescent patients suggests 
that the eradication of this virus is difficult, necessitating the 
development of an array of anti-viral therapeutic approach-
es. It also calls for better understanding of the molecular 
basis of EBOV infection and related pathogenesis. 
Virus attachment and membrane fusion are the initial 
steps in the entry process. Many host cell attachment fac-
tors, such as C-type lectins, including DC-SIGN (dendritic 
cell-specific ICAM3-grabbing non-integrin; also known as 
CD209) and L-SIGN (liver and lymph node SIGN; also 
known as CLEC4M), and several cell surface proteins, in-
cluding integrins, T cell immunoglobulin, and mucin do-
main-containing (TIM) proteins and tyrosine protein kinase 
receptor 3 (TYRO3) family members, are involved in 
EBOV attachment. The same team has also resolved the 
co-crystal structures of human TIM proteins complexed 
with the ligand, phosphatidylserine (Wang et al., 2015) 
When the EBOV attaches to the host cell membrane, it is 
“swallowed” by a macropinocytosis-like process, following 
which it traffics through the early and late endosomes. In 
the endosomes, the glycoprotein (GP) present on the enve-
lope of EBOV is cleaved by cysteine enzymes (cathepsins B 
and L) of the host cells into a “primed” form, thereby ex-
posing the receptor binding site to the endosomal receptor 
NPC1. NPC1 is a ubiquitously expressed protein with 13 
trans-membrane domains residing mainly in the limiting 
membranes of the late endosomes and lysosomes. It func-
tions to transport cholesterol with the help of a soluble 
NPC2 protein. EBOV licenses NPC1 molecule as the “key” 
to enter host cells. Since many years, virologists have been 
trying to understand the nature of the primed EBOV glyco-
protein interacting with the NPC1 molecule. 
Gao’s team spent three years to solve the crystal structure 
of the second luminal domain (domain C) of NPC1 mole-
cule (NPC1-C), which is responsible for the binding of the 
primed EBOV glycoprotein. They showed that NPC1-C has 
a helical core structure surrounded by several β-strands, 
with two protruding loops. Furthermore, they determined 
the complex structure formed between the primed glyco-
protein and NPC1-C. People can see for the first time that 
NPC1-C utilizes its two protruding loops to contact a hy-
drophobic cavity present on the top of the primed glycopro-
tein. Interestingly, one protruding loop deeply inserts into 
the cavity, analogous to a “key” being inserting into the 
hole of a “lock”. It is expected that future drug candidates 
can be designed to block the hole of this “lock”, to prevent 
virus infection. Scientists have found several NPC1-target- 
ing compounds that can inhibit EBOV infection. However, 
these drug candidates caused severe side effects during 
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clinical trials, attributable to the physiological roles of 
NPC1. This key-lock feature revealed in the Cell paper pro-
vides a new concept for designing drugs targeting the hole 
of “lock” in EBOV glycoprotein, in the hope to reduce tox-
icity. 
In addition, a new membrane fusion mechanism has been 
proposed by the authors. They identified several conforma-
tional changes in the primed glycoprotein, upon enzymatic 
cleavage and after NPC1-C binding. The upward movement 
of a short helix in the β3-α1 loop of GP1 subunit likely 
helps to release the N-terminal portion of the IFL (internal 
fusion loop) in the GP2 subunit, which probably triggers the 
membrane fusion. The four major types of membrane fusion 
are as follows: (i) interaction of the fusion protein with a 
cell surface receptor; (ii) sequential interactions with a cell 
surface receptor and co-receptor(s); (iii) exposure to a 
low-pH environment in endosomes after being engulfed 
(e.g., endocytosis); and (iv) sequential interactions with a 
cell surface receptor followed by exposure to low-pH envi-
ronment in endosomes. The new finding in the paper would 
propose a fifth fusion triggering mechanism, i.e., exposure  
to a low-pH environment in the late endosomes before in-
teraction with an endosomal receptor. As the Marburg virus 
also has a similar hydrophobic cavity on top of its primed 
glycoprotein and needs NPC1 for membrane fusion, this 
fusion triggering mechanism likely represents a unique fea-
ture of filoviruses. 
On January 14, 2016, WHO declared the end of the Ebo-
la outbreak in West Africa. One day later, a new case report 
of Ebola infection occurred in Sierra Leone. Such instances 
alarm the scientific community to invest more effort in 
eradicating the deadly virus. 
Compliance and ethics  The author(s) declare that they have no conflict 
of interest. 
Wang, H., Shi, Y., Song, J., Qi, J., Lu, G., Yan, J., and Gao, G.F. (2016). 
Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick 
C1. Cell 164, 258268. 
Wang, H., Qi, J., Liu, N., Li, Y., Gao, J., Zhang, T., Chai, Y., Gao, F., 
Zhang, H., Li, X., Ye, X., Yan, J., Lu, G., and Gao, G.F. (2015). Crystal 
structures of human TIM members: Ebolavirus entry-enhancing recep-
tors (in Chinese). Chin Sci Bull 60, 34383453 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
